Get started
Author

Till Wallrabenstein

Observed names: T Wallrabenstein, T. Wallrabenstein, Wallrabenstein, Till
Observed institutions: University of Freiburg, University Medical Center Freiburg, University Hospital of Basel, Kantonsspital Baselland, Kantonsspital Baselland Standort Bruderholz, University Hospital Ulm
ORCID: 0000-0002-6672-3135
Observed ORCID: 0000-0002-6672-3135
OpenAlex ID: A5077155140
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features
2016 · V I Gaidzik, V Teleanu, et al. · Leukemia · 287
Corticosteroid-resistant immune-related adverse events: a systematic review
2024 · Eveline Daetwyler, Till Wallrabenstein, et al. · Journal for ImmunoTherapy of Cancer · 84
PDF
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
2025 · Lukas M. Braun, Sophie Giesler, et al. · Cancer Cell · 64
Erratum: RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features
2016 · V I Gaidzik, V Teleanu, et al. · Leukemia · 64
PDF
Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer
2020 · Till Wallrabenstein, Jessica Del Rio, et al. · PLoS ONE · 11
PDF
Pegylated liposomal doxorubicin ( PLD ) in daily practice—A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer
2023 · T. Wallrabenstein, E. Daetwyler, et al. · Cancer Medicine · 5
PDF
Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study
2023 · Till Wallrabenstein, Maximilian Mamot, et al. · JTO Clinical and Research Reports · 5
Comparison of a Novel MRNA-Based Breast Cancer Subtyping Assay with PAM50 and Oncotype DX in Estrogen Receptor-Positive/HER2-Negative Breast Cancer: An Exploratory Age-Stratified Retrospective Cohort Study
2026 · Till Wallrabenstein, Elena Diana Chiru, et al. · Current Issues in Molecular Biology · 1
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial
2026 · Roxane Riemer, Lukas M. Braun, et al. · Nature Communications
PDF
Immunotherapy with Pembrolizumab beyond Progression and Local Ablative Therapy in Oligoprogressive Metastatic Non-Small Cell Lung Cancer
2026 · Anton Oseledchyk, Leopold Häcker, et al. · Oncology Research and Treatment
PDF
Implications of vitamin D levels in elderly non-small cell lung cancer patients: A retrospective cohort analysis
2025 · E. Su, N. Railic, et al. · Journal of Geriatric Oncology
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
2025 · Braun, Lukas M, Giesler, Sophie, et al. · Zurich Open Repository and Archive (University of Zurich)
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
2025 · Braun, Lukas M., Giesler, Sophie, et al. · Zurich Open Repository and Archive (University of Zurich)
Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer
2023 · Till Wallrabenstein, Anton Oseledchyk, et al. · Cancers
PDF
Pegylated liposomal doxorubicin (PLD) in daily practice – A single center experience of treatment with PLD in elderly and co-morbid patients with metastatic breast cancer
2022 · T. Wallrabenstein, E.S. Daetwyler, et al. · Journal of Geriatric Oncology
Clinical characterization and prognostic impact of SF3B1 and TP53 gene mutations in myelodysplastic syndromes
2017 · Wallrabenstein, Till · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University)
PDF
Works count: 16
Citation count: 521
H-index: 5
I10-index: 5
Year
Topic
Type